Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 12/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 11/20 | 0.48 |
| ▸ | CACNA1I | Q9P0X4 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1789625 | 1.00 | CACNA1H (0.48) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL1789193 | 0.89 | MEN1 (0.45) | CACNA1GCACNA1IALDH1A1KMT2ACNR2 | |
| SCHEMBL30814174 | 0.89 | MEN1 (0.45) | CACNA1GCACNA1IALDH1A1KMT2ACNR2 | |
| SCHEMBL30795856 | 0.87 | LMNA (0.52) | CNR2LMNAPOLB | |
| SCHEMBL1786577 | 0.87 | LMNA (0.52) | CNR2LMNAPOLB | |
| SCHEMBL30795173 | 0.86 | KDM4E (0.49) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL1788526 | 0.86 | KDM4E (0.49) | CACNA1HCACNA1GCACNA1IALDH1A1KMT2A | |
| SCHEMBL30796432 | 0.85 | PTGS2 (0.43) | ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL1786193 | 0.85 | PTGS2 (0.43) | ALDH1A1KMT2ALMNAPOLB | |
| SCHEMBL1788705 | 0.82 | RIOK2 (0.47) | ALDH1A1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |